BioCentury | Sep 5, 2005
Clinical News

ACP-SL017: Phase I start

AAF will begin an open-label, dose-escalation, Phase I trial in patients to evaluate ACP-SL017 with and without photoactivation. The company expects to complete the trial before the year end. Altachem Pharma Ltd. (CDNX:AAF), Edmonton, Alberta...
BioCentury | Jan 3, 2005
Company News

Altachem management update

Altachem Pharma Ltd. (CDNX:AAF), Edmonton, Alberta Business: Infectious, Cancer Resigned: Warren Jackson as EVP of international business WIR Staff cancer Infectious...
BioCentury | Dec 20, 2004
Company News

Altachem board of directors update

Altachem Pharma Ltd. (TSE:AAF), Edmonton, Alberta Business: Infectious, Cancer Resigned: Robert Sydenham and Warren Jackson Appointed: Ragupathy Madiyalakan, a director, as chairman WIR Staff...
BioCentury | Aug 9, 2004
Company News

Isotechnika Inc., Altachem deal

ISA acquired AAF's breath kit manufacturing business for C$500,000 (US$376,150). ISA paid C$300,000 up front and will pay the remaining C$200,000 in the form of royalties on kits produced. AAF had been ISA's exclusive manufacturer...
BioCentury | Jan 6, 2003
Company News

Altachem board of directors update

Altachem Pharma Ltd. (TSE:AAF), Edmonton, Alberta Business: Infectious diseases, Cancer Resigned: Madi Madiyalakan WIR Staff cancer Infectious...
BioCentury | Jan 6, 2003
Company News

Altachem management update

Altachem Pharma Ltd. (TSE:AAF), Edmonton, Alberta Business: Infectious diseases, Cancer Resigned: Madi Madiyalakan as EVP of R&D WIR Staff cancer Infectious...
BioCentury | Apr 1, 2002
Clinical News

Altachem preclinical data

Hypocrellin compounds activated using ultrasound delayed tumor growth in mice and in human leukemia in culture. Data were presented at the Symposium on Sonodynamic Therapy in Fukuoka. Altachem Pharma Ltd. (CDNX:AAF), Edmonton, Alberta Product: Ultrasound-activated...
BioCentury | Mar 25, 2002
Company News

Altachem deal

AAF purchased from an undisclosed party exclusive rights to an immunomodulator for 400,000 AAF shares valued at C$920,000 (US$580,980) based on AAF’s Friday close at C$2.30. AAF plans to use the preclinical product alone and...
BioCentury | Apr 19, 1999
Company News

Steroidogenesis Inhibitors International, Altachem-Pharma Ltd. deal

STGI received a $50,000 license payment from AAF for the use of STGI's Anticort procaine anti-cortisol immune booster to treat HIV in Canada. The payment brings the final total of license fees that STGI has...
BioCentury | Apr 12, 1999
Clinical News

Anticort procaine: Began Phase I testing

Steroidogenesis Inhibitors International (STGI), Las Vegas, Nev. Product: Anticort procaine Business: Infectious diseases Therapeutic category: Immune stimulation Target: Cortisol Description: Procaine anti-cortisol immune booster Indication: Treat HIV infection/AIDS Status: Altachem Pharma Ltd. (ASE:AAF, Edmonton, Alberta),...
Items per page:
1 - 10 of 10
BioCentury | Sep 5, 2005
Clinical News

ACP-SL017: Phase I start

AAF will begin an open-label, dose-escalation, Phase I trial in patients to evaluate ACP-SL017 with and without photoactivation. The company expects to complete the trial before the year end. Altachem Pharma Ltd. (CDNX:AAF), Edmonton, Alberta...
BioCentury | Jan 3, 2005
Company News

Altachem management update

Altachem Pharma Ltd. (CDNX:AAF), Edmonton, Alberta Business: Infectious, Cancer Resigned: Warren Jackson as EVP of international business WIR Staff cancer Infectious...
BioCentury | Dec 20, 2004
Company News

Altachem board of directors update

Altachem Pharma Ltd. (TSE:AAF), Edmonton, Alberta Business: Infectious, Cancer Resigned: Robert Sydenham and Warren Jackson Appointed: Ragupathy Madiyalakan, a director, as chairman WIR Staff...
BioCentury | Aug 9, 2004
Company News

Isotechnika Inc., Altachem deal

ISA acquired AAF's breath kit manufacturing business for C$500,000 (US$376,150). ISA paid C$300,000 up front and will pay the remaining C$200,000 in the form of royalties on kits produced. AAF had been ISA's exclusive manufacturer...
BioCentury | Jan 6, 2003
Company News

Altachem board of directors update

Altachem Pharma Ltd. (TSE:AAF), Edmonton, Alberta Business: Infectious diseases, Cancer Resigned: Madi Madiyalakan WIR Staff cancer Infectious...
BioCentury | Jan 6, 2003
Company News

Altachem management update

Altachem Pharma Ltd. (TSE:AAF), Edmonton, Alberta Business: Infectious diseases, Cancer Resigned: Madi Madiyalakan as EVP of R&D WIR Staff cancer Infectious...
BioCentury | Apr 1, 2002
Clinical News

Altachem preclinical data

Hypocrellin compounds activated using ultrasound delayed tumor growth in mice and in human leukemia in culture. Data were presented at the Symposium on Sonodynamic Therapy in Fukuoka. Altachem Pharma Ltd. (CDNX:AAF), Edmonton, Alberta Product: Ultrasound-activated...
BioCentury | Mar 25, 2002
Company News

Altachem deal

AAF purchased from an undisclosed party exclusive rights to an immunomodulator for 400,000 AAF shares valued at C$920,000 (US$580,980) based on AAF’s Friday close at C$2.30. AAF plans to use the preclinical product alone and...
BioCentury | Apr 19, 1999
Company News

Steroidogenesis Inhibitors International, Altachem-Pharma Ltd. deal

STGI received a $50,000 license payment from AAF for the use of STGI's Anticort procaine anti-cortisol immune booster to treat HIV in Canada. The payment brings the final total of license fees that STGI has...
BioCentury | Apr 12, 1999
Clinical News

Anticort procaine: Began Phase I testing

Steroidogenesis Inhibitors International (STGI), Las Vegas, Nev. Product: Anticort procaine Business: Infectious diseases Therapeutic category: Immune stimulation Target: Cortisol Description: Procaine anti-cortisol immune booster Indication: Treat HIV infection/AIDS Status: Altachem Pharma Ltd. (ASE:AAF, Edmonton, Alberta),...
Items per page:
1 - 10 of 10